Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Citing “unprecedented demand,” drugmaker Novo Nordisk said Thursday it expects supply restrictions on starter doses of the weight loss medicine Wegovy to persist into 2024, several months ...

Novo Nordisk is already struggling to keep pace with runaway demand for Wegovy, which clinical trials have shown can help people lose 15% of their body weight after less than 16 months.

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...